TC Biopharm to test virus-killing cell therapy on Covid-19 patients

Published on 
February 17, 2021
Investing Women

Motherwell-based biotech company TC BioPharm (TCB) is to begin clinical trials of an experimental therapy designed to kill Covid-19 infected cells. TCB previously used gamma-delta T cells (GDTs) donated from healthy volunteers to treat cancer patients and believes they could boost the immune system of those being treated for Covid. It has now gained regulatory approval.

Load More

© Investing Women Angels Limited (Company Number SC462552) is a company incorporated in Scotland under the Companies Acts. Registered Office at 2nd Floor, Elder House, Multrees Walk, Edinburgh, EH1 3DX

menu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram